Inconsistency Among Utility Values in Japanese Studies –Are All QALYs Created Equal?

Published Jun 30, 2014
Tochigi, Japan - To conduct cost–utility analyses (CUAs) for pharmaceuticals, substantial data are required. One part of these data contains the utility values used when calculating the quality-adjusted life year (QALY). Using utility data in clinical trials in Japan was uncommon; therefore, published literature was the main data source of eliciting utility values in CUAs. By conducting a systematic review of published literature, researchers from the Graduate School of Pharmacy at the International University of Health and Welfare and Eisai Co., Ltd. Government Relations provided an overview of how current utility values were obtained in CUAs for pharmaceuticals in Japan, with reference to the methodological guidelines developed in the United Kingdom, Australia, Canada, France, and Japan. Japanese CUAs used utility values from various sources with different methods and a variety of instruments, such as the EuroQol 5D (EQ-5D) and the time trade-off (TTO) method. Utility values were derived from studies conducted at different locations worldwide, and only a few CUAs explained their rationale for selecting the studies for their utility values. Dr. Shunya Ikeda, MD, DMSc, Professor of Pharmacoeconomics and Public Health at the International University of Health and Welfare in Japan, and co-author of the study said, “Our study implies that QALYs and incremental cost-effectiveness ratios (ICERs) might be inconsistent among current CUAs conducted in Japan. When the Japanese government introduces CUAs for reimbursement or pricing decisions, standardization of the method to obtain utility values is strongly recommended.” The full study, “Investigation of Evidence Sources for Health-Related QOL in Cost-Utility Analysis of Pharmaceuticals in Japan” is published in Value in Health Regional Issues, Volume 3.

Value in Health Regional Issues (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Follow Value in Health Regional Issues on Twitter: @ISPORJournals

 

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×